drugset / Trial / NCT05765032

Study of SHR-A1921 in Combination With Other Anti-cancer Agents in Patients With Advanced Solid Tumors

NCT05765032

Phase 1/2 Active not recruiting 220 enrolled Suzhou Suncadia Biopharmaceuticals Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This research study is a multicentre phase Ⅰb/Ⅱ Study to evaluate the efficacy and safety of SHR-A1921 in combination with other anti-cancer agents in patients with advanced solid tumors

Timeline

Start
2022-12-30
Primary completion
2025-04-30
Completion
2026-02-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Adebrelimab Monoclonal antibody Intravenous
Subject Bevacizumab Monoclonal antibody Intravenous
Subject Carboplatin Small molecule Intravenous
Subject Cisplatin Other / unclassified Intravenous
Subject SHR-A1921 Monoclonal antibody Intravenous

Indications